Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients
© I. Holzapfel Publishers 2009
Received: 18 June 2009
Accepted: 22 July 2009
Published: 12 September 2009
Breast cancer (BC) represents one of the leading causes of cancer related deaths worldwide. New tools for diagnostic staging and therapeutic monitoring are needed to improve individualized therapies and improve clinical outcome. The analyses of circulating tumour cells may provide important prognostic information in the clinical setting.
Materials and methods
Circulating tumour cells (CTC) of 63 BC patients were isolated from peripheral blood (PB) through immunomagnetic separation. Subsequently, RT-PCR or mPCR for the genes ga733.2, muc-1, c-erbB2, mgb-1, spdef and c-erbB2 were performed. Subsequently, expression data were correlated with the tumour stages. Fourteen healthy individuals served as controls.
Significant correlations with tumour stages were found in single gene analyses of ga733.2, muc-1 and in multi-gene analyses of ga733.2/muc-1/mgb1/spdef. Furthermore, a significant correlation of Ca 15-3 and all studied genes was also observed.
Herein, we demonstrated a positive correlation of a gene signature consisting of ga733.2, muc-1, mgb1 and spdef and advanced stages of BC. Moreover, all studied genes and gene patterns revealed a significant correlation with Ca 15-3 positive cases.
KeywordsMamma carcinoma gene signature real-time-PCR
Even though new developments in clinical research on breast cancer (BC) have provided clinicians with a set of important diagnostic tools, there is still an urgent need for further, more sensitive staging techniques. Recent studies have shown that quantitative and qualitative analyses of circulating tumour cells (CTC) may provide prognostic information in BC [1, 2]. Attempts to isolate CTC in peripheral blood (PB) date back to more than 100 years . Sandberg et al. isolated CTC from BC patients using centrifugation and fibrinogen to aggregate erythrocytes . Notably, Hsieh et al. reported that the absolute count of CTC may be related to an aggressive course of disease in BC patients . First attempts to isolate CTC through immunomagnetic separation were made by Berois et al using a CK-19 on BC cell lines . This technique was recently successfully used by Hardingham et al. in patients with gastrointestinal neoplasias . Combining immunomagnectic separation and real-time-PCR (RT-PCR), this group could positively correlate the presence of CTC in PB with shorter disease-free intervals.
Gene profile analyses of certain putative genetic markers may lead to sensitive and specific CTC detection and may enable an improvement in the outcome prediction [8–13]. In fact, PCR and RT-PCR can be applied to perform expression analyses of immunomagnectically isolated CTC. In a previous study we analysed the CTC of 63 BC patients in various disease stages and identified the genes ga733.2, muc-1, mgb1 and spdef as putative markers for CTC detection. Based upon our previous data, in this study we performed correlation analyses between the detected gene expression levels and the known clinical staging of breast cancer. Furthermore, we compared the gene expression data with the detected Ca15-3 serum levels. Increased serum levels of the tumour marker Ca 15-3 have been associated with advanced disease and poor outcome in several studies [14, 15].
Materials and methods
Our study population consisted of 63 BC patients and 14 healthy controls. 50 patients with first diagnosed disease (FD) and 13 patients with metastatic disease (MD) in various disease stages were enrolled. All patients provided written informed consent. After peripheral venous blood sampling, CTC were separated using an immunomagnetic method (Adnagen Breast Cancer Select Kit) according to the instructions of the manufacturer (Adnagen). Cell lysates underwent mRNA isolation and reverse transcription following the manufacturer's instructions (Promega). Subsequently, mPCR for the genes ga733.2 and muc-1 and RT-PCRfor the genes mgb1 and spdef were performed. The resulting gene profiles were then compared with tumour stage according to the TNM grading system and tumour stage of the American Joint Committee on Cancer (AJCC) . Additionally, CTC profiling was compared to ELISA-determined Ca 15-3 positivity. Correlations were performed either by Pearson's two-sided χ2-test for dichotomized values or by Pearson's bivariate correlation for values with two thresholds. Significance was defined by p < 0.05.
Correlation to disease state
Single gene expression and gene patterns were correlated to first diagnosed disease (FD) and metastatic disease (MD). Only mgb1 was significantly correlated to MD (p = 0.019) but not to FD, whereas spdef, muc-1, ga733.2 and c-erbB2 did not correlate with disease stage. Consecutive multiple gene evaluations demonstrated significance for the pattern ga733.2/muc-1 (p = 0.045). The gene pattern ga733.2/muc-1/spdef/mgb1 showed a significant correlation with MD (p = 0.023).
Correlation to tumour stage
Correlation to disease staging.
ga733.2 / muc-1
Correlation to nodal status
Correlation to nodal status.
ga733.2 / muc-1
Correlation to distant metastases
Correlation to distant metastases.
Presence of distant metastases
ga733.2 / muc-1
Correlation to Ca 15-3 status
Correlation to Ca 15-3.
Ca 15-3 status
ga733.2 / muc-1
Haematological dissemination of malignant cells is a prerequisite to distant organ metastases in many cancer entities [21–24]. Yet, several studies suggest that only a minority of tumour cells have the ability to invade and metastasize [17–19]. Therefore, it is crucial to investigate which genes ultimately facilitate tissue invasion and disease progression.
Here, we propose an association between a certain set of genes (ga733.2, muc-1, mgb1 and spdef) and advanced tumour stages in BC. Notably, the studied gene signature exposed a significant correlation with stage levels IIIa or higher. Herein, muc-1 expression significantly correlated with nodal and distant metastases, and hence higher staging levels. In line with these results, it has been recently shown that a muc-1-induced tumourigenesis gene signature could predict disease-free and overall survival in patients with breast and lung cancer .
All investigated genes and gene profiles were significantly correlated with Ca 15-3 positivity. Since elevated levels of this tumour marker have been shown to predict the outcome in BC, the gene signature we analyzed is likely to hold prognostic relevance.
The present investigation poses several questions: First, since the analyses was not performed in a prospective manner, it is impossible to determine whether the detected gene profiles in patients with late disease might also be present in early stages of the disease. Second, it remains to be studied whether CTC exhibit a daily or hourly fluctuation in the gene expression levels. This could lead to false negative results in the proposed method.
In summary, our data indicate a notable correlation between the studied genes (ga733.2, muc-1, mgb1 and spdef) and advanced disease in BC. Accordingly, the studied genes might play a role in the process of metastases formation. However, prospective studies in a larger patient population are needed to further validate the proposed hypothesis.
circulating tumour cells
- c-erbB2 :
cellular avian erythroblastosis homologue B2
- ga733.2 :
major gastrointestinal tumour-associated protein
- muc-1 :
- mgb-1 :
polymerase chain reaction
reverse transcriptase polymerase chain reaction
- spdef :
SAM pointed domain- containing ETS transcription factor
This work is dedicated to Kim and Thomas Speer. Furthermore this work is a part of the thesis of Burak Dogan
- Wang L, Wang Y, Liu Y, Cheng M, Wu X, Wei H: Flow cytometric analysis of CK19 expression in the peripheral blood of breast carcinoma patients: relevance for circulating tumor cell detection. J Exp Clin Cancer Res 2009,28(1):57. 10.1186/1756-9966-28-57PubMed CentralPubMedView ArticleGoogle Scholar
- Cristofanilli M, Hayes DF, Budd GT, et al.: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23: 1420–30. 10.1200/JCO.2005.08.140PubMedView ArticleGoogle Scholar
- Ashworth TR: A Case of Cancer in which cells similar to those in the tumors were seen in the blood after death. Australian Medl J 1869, 146–148.Google Scholar
- Sandberg AA, Moore GE: Examination of blood for tumor cells. J Natl Cancer Inst 1957,19(1):1–11.PubMedGoogle Scholar
- Hsieh HB, Marrinucci D, Bethel K, et al.: High speed detection of circulating tumor cells. Biosens Bioelectron 2006, (21):1893–9.
- Berois N, et al.: Detection of rare human breast cancer cells. Comparison of an immunomagnetic separation method with immunocytochemistry and RT-PCR. Anticancer Res 1997,17(4A):2639–46.PubMedGoogle Scholar
- Hardingham JE, et al.: Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer 2000,89(1):8–13. 10.1002/(SICI)1097-0215(20000120)89:1<8::AID-IJC2>3.0.CO;2-KPubMedView ArticleGoogle Scholar
- Siegel PM, Dankort DL, Hardy WR, Muller WJ: Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 1994, 14: 7068–77.PubMed CentralPubMedGoogle Scholar
- Oh JJ, Grosshans DR, Wong SG, Slamon DJ: Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. Nucleic Acids Res 1999, 27: 4008–17. 10.1093/nar/27.20.4008PubMed CentralPubMedView ArticleGoogle Scholar
- Siegel PM, Ryan ED, Cardiff RD, Muller WJ: Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. Embo J 1999, 18: 2149–64. 10.1093/emboj/18.8.2149PubMed CentralPubMedView ArticleGoogle Scholar
- Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al.: Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990, 265: 15286–93.PubMedGoogle Scholar
- Eltahir EM, Mallinson DS, Birnie GD, Hagan C, George WD, Purushotham AD: Putative markers for the detection of breast carcinoma cells in blood. Br J Cancer 1998, 77: 1203–7. 10.1038/bjc.1998.203PubMed CentralPubMedView ArticleGoogle Scholar
- Lambrechts AC, van't Veer LJ, Rodenhuis S: The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol 1998, 9: 1269–76. 10.1023/A:1008445604263PubMedView ArticleGoogle Scholar
- Pectasides D, Pavlidis N, Gogou L, Antoniou F, Nicolaides C, Tsikalakis D: Clinical value of Ca 15–3, mucinlike carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am J Clin Oncol 1996,19(5):459–64. 10.1097/00000421-199610000-00007PubMedView ArticleGoogle Scholar
- Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, Lee KS: Preoperative Ca 15–3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008,19(4):675–81.PubMedView ArticleGoogle Scholar
- Greene PDFL, Fleming ID, et al.: AJCC Cancer Staging Manual. 6th edition. New York: Springer; 2002.View ArticleGoogle Scholar
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003,100(7):3983–8. 10.1073/pnas.0530291100PubMed CentralPubMedView ArticleGoogle Scholar
- Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994,367(6464):645–8. 10.1038/367645a0PubMedView ArticleGoogle Scholar
- Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2001,414(6859):105–11. 10.1038/35102167PubMedView ArticleGoogle Scholar
- Khodarev NN, Pitroda SP, Beckett MA, MacDermed DM, Huang L, Kufe DW, Weichselbaum RR: MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res 2009,69(7):2833–7. 10.1158/0008-5472.CAN-08-4513PubMed CentralPubMedView ArticleGoogle Scholar
- Bölke E, Peiper M, Budach W, Matuschek C, Schwarz A, Orth K, Gripp S: Unilateral keloid formation after bilateral breast surgery and unilateral radiation. Eur J Med Res 2007, 12: 320–322.PubMedGoogle Scholar
- Matthaei H, Boelke E, Eisenberger CF, Alldinger I, Krieg A, Schmelzle M, Poremba C, Schellhammer F, Knoefel WT, Budach W, Peiper M: Interdisciplinary treatment of primary hepatic angiosarcoma: emergency tumor embolization followed by elective surgery. Eur J Med Res 2008, 4: 591–594.Google Scholar
- Matthaei H, Bölke E, Schmelzle M, Budach W, Orth K, Engers R, Cohnen M, Matuschek C, Gripp S, Knoefel WT, Peiper M: Modern therapy of rectal carcinoma. Eur J Med Res 2008, 13: 139–146.PubMedGoogle Scholar
- Peiper M, Bölke E, Orth K, Hosch SB, Rehders A, Matthaei A, Knoefel WT: Current status of radical systematic lymphadenectomy in pancreatic cancer review of the literature. Eur J Med Res 2007, 12: 1–7.Google Scholar